Can azithromycin be used to treat acute diarrhea in a healthy patient ≥12 years old with suspected bacterial (traveler’s) infection?

Azithromycin for Acute Diarrhea

Yes, azithromycin is an excellent choice for treating acute bacterial (traveler's) diarrhea in healthy patients ≥12 years old, particularly for moderate-to-severe cases and especially when dysentery is present. 1

Treatment Algorithm by Severity

Mild Diarrhea (tolerable, not distressing, doesn't interfere with activities)

• Do NOT use antibiotics 1
• Use loperamide or bismuth subsalicylate instead
• Reserve antibiotics for progression to moderate/severe disease

Moderate Diarrhea (distressing or interferes with planned activities)

• Azithromycin may be used (Strong recommendation, high level of evidence) 1
• Dosing: Either single 1-gram dose OR 500 mg daily for 3 days 1
• Alternative options include fluoroquinolones (with caveats below) or rifaximin
• Loperamide can be added as adjunctive therapy or used alone

Severe Diarrhea (incapacitating or prevents planned activities; ALL dysentery)

• Azithromycin is the PREFERRED first-line agent (Strong recommendation, moderate-to-high level of evidence) 1
• This is particularly critical for:
  • Any dysentery (grossly bloody stools mixed with stool in commode)
  • Watery diarrhea with more than mild fever
  • Travel to Southeast Asia or other high fluoroquinolone-resistance areas

Why Azithromycin is Preferred

Resistance patterns strongly favor azithromycin over fluoroquinolones. In Thailand, azithromycin demonstrated 96% cure rates at 72 hours versus only 71% for levofloxacin, with fluoroquinolone resistance exceeding 90% in Campylobacter species 2. This superiority has been demonstrated globally, not just in Southeast Asia 1.

Azithromycin covers the key invasive pathogens that cause dysentery and severe disease:

• Campylobacter (including fluoroquinolone-resistant strains)
• Shigella species
• Enteroinvasive E. coli
• Aeromonas, Plesiomonas, and Yersinia species 1

Single-dose regimens are highly effective. A randomized trial comparing single-dose azithromycin (500 mg) with levofloxacin showed azithromycin was non-inferior at 24 hours (78.3% vs 81.4% cure rates) and equivalent by 48-72 hours (approximately 91% and 96% respectively) 3. The single 1-gram dose may be split over the first day to reduce nausea 1.

Important Caveats and Pitfalls

Post-dose nausea is the main side effect. Approximately 14% of patients experience mild, self-limited nausea within 30 minutes of taking single-dose azithromycin, compared to <6% with other regimens 2. This is exacerbated by the underlying gastrointestinal infection but rarely requires intervention 1.

Distinguish true dysentery from hemorrhoids. Educate patients that dysentery means gross blood admixed with stool in the commode, NOT just streaks of blood on toilet paper (which likely represents hemorrhoids) 1.

Fluoroquinolones have significant limitations:

• FDA black box warning for Achilles tendon rupture 4
• Increased C. difficile risk
• Gut dysbiosis and acquisition of multidrug-resistant bacteria during travel 1
• Widespread Campylobacter resistance globally (not just Southeast Asia) 1
• Should be avoided for dysentery 1

Rifaximin cannot be used for invasive disease. It fails in up to 50% of cases with invasive pathogens and is inappropriate for dysentery or when fever/bloody stools suggest invasive infection 1. Reserve rifaximin only for non-invasive watery diarrhea.

When NOT to Use Azithromycin

Avoid antibiotics entirely for mild traveler's diarrhea where symptoms are tolerable and don't interfere with activities 1. The FDA label emphasizes that prescribing azithromycin without proven or strongly suspected bacterial infection increases resistance risk 4.

Consider testing rather than empiric treatment if diarrhea persists beyond 14 days, as this may indicate parasitic infection requiring different therapy 1, 5.

Practical Prescribing

The evidence supports azithromycin as first-line empiric therapy for moderate-to-severe acute bacterial diarrhea in travelers ≥12 years old. The single 1-gram dose offers convenience and comparable efficacy to 3-day regimens 3, 2, 6. For patients concerned about nausea, splitting the 1-gram dose over the first day is reasonable, though formal evidence for this approach is limited 1.

Loperamide can be safely added as adjunctive therapy to speed symptom resolution, reducing time to last unformed stool 1. However, avoid loperamide monotherapy in severe disease or when invasive infection is suspected.